Get the Stockscreener App
44.83
3.92%
1.69
Artivion Inc stock is traded at $44.83, with a volume of 660.73K.
It is up +3.92% in the last 24 hours and up +47.47% over the past month.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
See More
Previous Close:
$43.14
Open:
$43.46
24h Volume:
660.73K
Relative Volume:
1.65
Market Cap:
$2.12B
Revenue:
$384.90M
Net Income/Loss:
$-851.00K
P/E Ratio:
-2,241.50
EPS:
-0.02
Net Cash Flow:
$12.83M
1W Performance:
+4.72%
1M Performance:
+47.47%
6M Performance:
+58.63%
1Y Performance:
+75.67%
1-Day Range:
$43.12
$45.07
1-Week Range:
$41.60
$45.07
52-Week Range:
$21.97
$45.07
Artivion Inc Stock (AORT) Company Profile
Name
Artivion Inc
Sector
Industry
Phone
(770) 419-3355
Address
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
44.83 | 2.02B | 384.90M | -851.00K | 12.83M | -0.02 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-17-25 | Initiated | Canaccord Genuity | Buy |
| Oct-23-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-22 | Reiterated | Lake Street | Buy |
| Aug-08-22 | Initiated | Lake Street | Buy |
| Mar-03-22 | Initiated | Stifel | Buy |
View All
Artivion Inc Stock (AORT) Latest News
Artivion Inc. Inches Above Key Support — Safe to HoldRate Cut & Short-Term Trading Alerts - thegnnews.com
Artivion's Insider Transactions: A Governance and Liquidity Lens into Q2 2025 Performance - AInvest
Artivion CEO Mackin sells $528k in shares - Investing.com
Artivion price target raised to $41 from $35 at Canaccord - MSN
Artivion Inc. Building a Base Near SupportWeekly Investment Summary & AI Powered Market Trend Analysis - beatles.ru
Price Floor Holding on Artivion Inc. — Rebound PossibleWeekly Profit Recap & Community Verified Trade Signals - metrotimes.co.kr
Can Artivion Inc. ride the EV wave2025 Volume Leaders & Free Expert Verified Stock Movement Alerts - newsyoung.net
Is Artivion Inc. stock heavily shortedJuly 2025 News Drivers & Real-Time Volume Trigger Notifications - newsyoung.net
Reversal Confirmed Artivion Inc. Stock Rallies Above MAJuly 2025 Short Interest & Daily Profit Maximizing Tips - newsimpact.co.kr
Artivion's Strong Financials and Promising Pipeline Justify Buy Rating - AInvest
Real Time Chart Alerts Flash Bullish on Artivion Inc.Forecast Cut & Safe Capital Growth Tips - sundaytimes.kr
Artivion Inc. Attempts Reversal From Key SupportGDP Growth & AI Driven Price Predictions - classian.co.kr
Artivion SVP Holloway sells $1m in shares after option exercise - Investing.com
Artivion’s chief commercial officer Davis sells $471k in shares - Investing.com
Artivion’s chief commercial officer Davis sells $471k in shares By Investing.com - Investing.com UK
Artivion Insider Sold Shares Worth $471,756, According to a Recent SEC Filing - MarketScreener
Chart based analysis of Artivion Inc. trends2025 Institutional Moves & Growth Focused Investment Plans - Newser
Earnings visualization tools for Artivion Inc.Weekly Volume Report & AI Driven Price Forecasts - Newser
Will Artivion Inc. stock benefit from interest rate changesPortfolio Value Summary & Daily Volume Surge Signals - Newser
Artivion stock hits 52-week high at 43.93 USD - Investing.com
Artivion stock hits 52-week high at 43.93 USD By Investing.com - Investing.com Canada
Artivion at Canaccord Conference: Strategic Growth and Innovation - Investing.com
Artivion at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Is this a good reentry point in Artivion Inc.July 2025 Action & Daily Growth Stock Investment Tips - Newser
Artivion, Inc. (NYSE:AORT) Stock Holdings Lifted by Natixis Advisors LLC - Defense World
Artivion's (AORT) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Is now a turning point for Artivion Inc.IPO Watch & AI Driven Stock Reports - Newser
Revenues Tell The Story For Artivion, Inc. (NYSE:AORT) As Its Stock Soars 37% - simplywall.st
Artivion, Inc. (NYSE:AORT) Q2 2025 Earnings Call Transcript - Insider Monkey
Technical signs of recovery in Artivion Inc.Reversal Signal Prediction Based on Volume - Newser
Artivion Inc. Reports Strong Q2 Earnings and Positive Outlook - TipRanks
Artivion Appoints Lance Berry as COO, Raises Earnings Guidance - AInvest
Artivion Appoints Lance Berry as COO - MarketScreener
Artivion Appoints Lance A. Berry as COO - TipRanks
Artivion Reaches Analyst Target Price - Nasdaq
Artivion Surges on Improved 2025 Financial Outlook - StocksToTrade
Artivion’s Stocks Surge as Q2 Financials Exceed Expectations - timothysykes.com
Artivion (NYSE:AORT) Earns “Buy” Rating from Needham & Company LLC - Defense World
Canaccord Genuity Group Forecasts Strong Price Appreciation for Artivion (NYSE:AORT) Stock - Defense World
What technical models suggest about Artivion Inc.’s comebackPredictive Short-Term Market Reversal Alerts - Newser
Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth - MSN
Artivion's Q2 Earnings Surge: A High-Margin Medical Innovation Play with Undervalued Potential - AInvest
Artivion, Inc.'s (NYSE:AORT) 26% Jump Shows Its Popularity With Investors - 富途牛牛
Artivion price target raised to $45 from $32 at Needham - Yahoo Finance
Artivion Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com
Artivion Elevates 2025 Revenue Projection Amid Strong Q2 Earnings - StocksToTrade
A Quick Look at Today's Ratings for Artivion(AORT.US), With a Forecast Between $40 to $45 - 富途牛牛
Artivion 2025 Q2 Earnings Strong Performance with Net Income Surges 163% - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Artivion, Inc. (NYSE:AORT) - Defense World
Artivion (NYSE:AORT) Shares Gap Up on Better-Than-Expected Earnings - Defense World
Artivion (NYSE:AORT) Stock Rating Upgraded by Wall Street Zen - Defense World
Artivion Inc Stock (AORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):